Rachel Vatnsdal
Stock Analyst at JP Morgan
(4.20)
# 445
Out of 4,876 analysts
63
Total ratings
53.49%
Success rate
15.74%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $11.73 | -23.27% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $35.93 | -8.15% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $123.56 | +53.77% | 6 | Apr 29, 2025 | |
| RVTY Revvity | Maintains: Neutral | $120 → $100 | $97.82 | +2.23% | 4 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $19.67 | -3.41% | 4 | Mar 6, 2025 | |
| WAT Waters | Maintains: Neutral | $380 → $390 | $352.41 | +10.67% | 4 | Mar 6, 2025 | |
| TEM Tempus AI | Downgrades: Neutral | $50 → $55 | $66.52 | -17.32% | 3 | Feb 25, 2025 | |
| GH Guardant Health | Maintains: Overweight | $50 → $55 | $50.86 | +8.14% | 1 | Feb 21, 2025 | |
| A Agilent Technologies | Maintains: Overweight | $165 → $160 | $119.17 | +34.26% | 6 | Nov 26, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $650 → $670 | $408.28 | +64.10% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $88 → $80 | $73.27 | +9.19% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $5.25 | +280.95% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.24 | - | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,184.54 | +18.19% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $6 | $11.79 | -49.11% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.29 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $41.80 | +115.31% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $198.80 | +35.81% | 4 | Dec 20, 2023 |
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $11.73
Upside: -23.27%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $35.93
Upside: -8.15%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $123.56
Upside: +53.77%
Revvity
Apr 29, 2025
Maintains: Neutral
Price Target: $120 → $100
Current: $97.82
Upside: +2.23%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $19.67
Upside: -3.41%
Waters
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $352.41
Upside: +10.67%
Tempus AI
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $66.52
Upside: -17.32%
Guardant Health
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $50.86
Upside: +8.14%
Agilent Technologies
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $119.17
Upside: +34.26%
Thermo Fisher Scientific
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $408.28
Upside: +64.10%
Aug 12, 2024
Maintains: Overweight
Price Target: $88 → $80
Current: $73.27
Upside: +9.19%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $5.25
Upside: +280.95%
Aug 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.24
Upside: -
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,184.54
Upside: +18.19%
Aug 2, 2024
Maintains: Overweight
Price Target: $5 → $6
Current: $11.79
Upside: -49.11%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.29
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $41.80
Upside: +115.31%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $198.80
Upside: +35.81%